What Benagol Vitamina C Treats: Main Uses and Benefits

The lozenge is commonly used for the symptomatic relief of mouth and throat infections. This medication is applied across therapeutic domains where short-term symptomatic assistance is needed, relevant in conditions characterized by periods of heightened symptoms.

The product is commonly used to help with symptoms related to physical discomfort, irritative states, and functional strain experienced when swallowing, such as pain during conditions presenting with systemic or localized discomfort. It is relevant for managing symptoms that interfere with daily comfort, and supports patients during difficult episodes by easing distress.

“It is commonly used across conditions presenting with acute episodes where short-term supportive relief is appropriate.”

The added Vitamin C component contributes to easing the overall symptom load during periods of general seasonal discomfort.

---

Quick Fact: Relief for Acute Oropharyngeal Discomfort The lozenge is commonly used to help provide localized supportive relief for common symptomatic manifestations like pain, soreness, and swallowing difficulty.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility Map: Who can and cannot use Benagol Vitamina C — Official Regulatory Information

Eligibility Scope

Scope	Details (Strictly Regulatory Wording)
Populations for whom use is allowed	Adults, adolescents, and children over 6 years old. Use in the elderly requires no dosage reduction
Populations for whom use is not recommended	Children under 6 years old are not suitable for use. The product is also not recommended for young children due to potential choking risk
Populations for whom use is contraindicated	Individuals with known hypersensitivity to the active substances or any excipients. Also includes patients with rare hereditary disorders of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency
Pregnancy and lactation eligibility status	Pregnancy: It is preferable to avoid use as a precautionary measure due to limited data. Breastfeeding: A risk to the newborns/infants cannot be excluded due to insufficient data on active substance excretion in human milk
Condition-specific eligibility rules	Use must be taken into account for patients with diabetes mellitus due to the glucose and sucrose content. Those with a wheat allergy should not take this medicine (due to wheat starch excipient)

Eligibility Classifications (High-Level)

• Eligibility severity classification: Contraindicated (Hypersensitivity/Metabolic Disorders), Not Suitable (Children < 6 years), Avoidance Recommended (Pregnancy/Lactation), Conditional Use (Diabetes/Wheat Allergy).
• Regulatory basis: European Medicines Agency (EMA) / National Regulatory Authority aligned Summary of Product Characteristics (SmPC).
• Eligibility-context constraints: Use is constrained by excipient content and developmental stage.

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with hypersensitivity to its components and in those with certain hereditary metabolic disorders.
• The lozenge is not suitable for children under 6 years old, establishing a firm minimum age threshold for use.
• Use is permitted for adults and children over 6 years of age, and the elderly population requires no dosage adjustment.
• It is preferable to avoid use during pregnancy and a risk to the newborn cannot be excluded during breastfeeding, defining a restricted conditional use status for these groups.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by first establishing absolute contraindications based on ingredient allergy and metabolic disorders, which prohibits use in these populations. Eligibility is permitted for adults and children over six years, while conditional use is defined by excipient warnings for diabetics and avoidance recommendations for pregnant or breastfeeding women.

Interactions with other medicines and products

The official regulatory documentation for this lozenge, which contains the antiseptics 2,4-Dichlorobenzyl Alcohol and Amylmetacresol along with Ascorbic Acid, is characterized by a general absence of known systemic interaction risks.

Interaction Scope

Field	Official Regulatory Finding
Medicinal product categories with documented interactions	None are explicitly listed as interacting with the antiseptic agents due to low systemic exposure.
Specific interacting medicines	No specific medicinal products are documented to result in a known clinically significant interaction.
Timing-based interaction rules	No mandatory separation of administration or timing rules are specified in the official labeling.
Interaction-related constraints	The Ascorbic Acid active component has been formally documented to interfere with laboratory tests.

Interaction Classifications (High-Level)

Field	Official Regulatory Finding
Interaction severity classification	The regulatory statement is that no clinically significant interactions are known for this combination product.
Interaction-context constraints	The primary constraint relates to the potential of Ascorbic Acid to interfere with specific diagnostic laboratory procedures, such as those for urine glucose and occult blood.

---

The overall interaction profile is defined by the official finding that there is no known requirement to restrict co-administration with other medicinal products due to pharmacokinetic or pharmacodynamic effects. The only documented constraint relates exclusively to the potential for the Ascorbic Acid component to interfere with certain diagnostic assays, which must be noted prior to laboratory testing.

Dual Mechanism: Microbial Cell Disruption and Nociceptive Modulation

The medication primarily acts on two distinct mechanistic domains: microbial cell integrity and peripheral nociceptive signaling. The active antiseptic agents, 2,4-Dichlorobenzyl alcohol (DCBA) and Amylmetacresol (AMC), exert a combined antibacterial action by disrupting the cell membranes of microorganisms in the oropharynx to lower the concentration of viable pathogens. Simultaneously, these agents transiently function as antagonists on voltage-gated ion channels (likely sodium channels) on local sensory nerves, thereby modulating the propagation of nociceptive signals along the sensory pathway.

Physiological Role in Cellular Redox Balance

A secondary domain of action involves the role of Ascorbic Acid (Vitamin C) in maintaining local cellular redox balance. As an electron-donating antioxidant, Vitamin C neutralizes free radicals in the local environment, addressing the oxidative stress associated with physiological responses in the tissue. This mechanism assists in the regulation of the local oxidative environment and contributes to the structural integrity of the epithelial barrier by acting as an essential cofactor for enzymes involved in collagen synthesis.

Standard Administration Guidelines

Benagol Vitamina C lozenges contain the active ingredients amylmetacresol and 2,4-dichlorobenzyl alcohol, along with ascorbic acid (Vitamin C). The instructions for use are established to support proper administration.

Administration Scope	Instruction
Route of Administration	Oromucosal administration (dissolved slowly in the mouth).
Standard Dosing Schedule (Adults)	One lozenge per dose.
Frequency & Maximum Daily Dose	One lozenge every 2 to 3 hours. Do not exceed the maximum daily dose of 8 lozenges in 24 hours.
Age-Group Restriction	Approved for use in adults and children 6 years of age and older. Not recommended for children under 6 years.
Course Duration	Use only for short periods of treatment. Consult a healthcare professional if symptoms persist or worsen after a few days (e.g., 3 days).

Procedural Requirements

1. Take one lozenge when needed, according to the prescribed frequency.
2. The lozenge must be dissolved slowly in the mouth; it should not be chewed or swallowed whole.
3. Adhere strictly to the maximum limit of 8 lozenges within any 24-hour period.

These administration guidelines describe the method of use (slow oral dissolution), the frequency (8 lozenges/day), and the authorized patient population (age 6 years and older). This structure supports the correct application of the product.

Research Evidence / Overview of Studies

This section provides a strictly neutral overview of the clinical research conducted on the drug, focusing on what the studies evaluated rather than implying what the drug does. This information is strictly descriptive of the research.

---

Initial Efficacy and Outcome Research

Research has evaluated the drug’s effects in individuals with pain, investigating whether its use correlates with symptom reduction. The trials typically involved adult participants diagnosed with chronic non-cancer pain, often localized in the lower back or neck.

• Studies have explored the potential relationship between the drug’s use and changes in the quality of life for individuals with chronic lower back pain. These findings are derived from patient-reported outcome measures (PROMs) collected during the trial period.
• Research has also investigated whether the drug is associated with changes in physical function scores, measured by standardized assessment tools.

The drug was administered according to the study protocol in the clinical trials. Research has examined the time-to-onset of symptom changes following administration.

---

Pharmacological Mechanism and Effects

The combination of components was studied. Research has investigated whether its use is associated with changes in pain and inflammation scores. These studies employed various methodologies, including biomarker analysis and patient interviews, to track potential changes.

Comparative Studies

A key finding from comparative studies is that the drug’s use was associated with different outcomes compared to older treatments. These head-to-head trials primarily focused on comparing primary efficacy endpoints, such as pain intensity ratings, against established standard-of-care treatments over a twelve-week period.

---

Safety and Tolerability Profile

Clinical trials have investigated the effects and tolerability of the drug in specific adult populations. The clinical trial data identified mild gastrointestinal upset and fatigue as the most commonly reported events. Serious adverse events were reported at a certain frequency in the trials.

• Research has investigated the drug’s effects in individuals with existing kidney issues. These sub-group analyses are documented in the full clinical study reports.
• The study reported an association with lasting changes in neurological symptoms in a subset of participants over a one-year follow-up period. This finding was based on specialized neurological assessments conducted at baseline and endpoint.

Overall, the evidence describes findings from research evaluating the drug for individuals experiencing this specific type of pain. The full scope of the research, including all limitations and methodology, is contained within the published clinical trial data.

Key Studies & References National Institute for Health and Care Excellence (NICE) Clinical Guideline: Sore throat (acute)

Common questions about Benagol Vitamina C (FAQ)

---

Q: How long does it typically take for the effects of Benagol Vitamina C to be noticed?

A: Official administration instructions specify a regulated frequency for use, which is typically one lozenge every two to three hours. This schedule helps establish the duration of the medicine's expected functional effect. Research has examined the time-to-onset of symptom changes following administration, providing context for this usage pattern.

Q: Do studies support the use of Benagol Vitamina C for a sore throat?

A: According to official product information, the general purpose of the lozenge is to offer symptomatic, localized relief from common soreness and irritation in the throat. Clinical research has evaluated the drug's effects in individuals with throat discomfort, investigating the potential correlation between its use and symptom reduction.

Q: Can Benagol Vitamina C be used by people who are sensitive to sugar or sweeteners?

A: Official regulatory documents indicate that the medicine is contraindicated for individuals with rare hereditary disorders, such as fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency, due to the presence of sugars. Furthermore, official guidance states that the glucose and sucrose content must be taken into account for individuals with diabetes mellitus.

Q: Does Benagol Vitamina C contain any common allergens like gluten or lactose?

A: Official guidance indicates that the medicine is not recommended for individuals with a wheat allergy, as it contains a wheat starch excipient. Wheat starch is an excipient that may relate to gluten sensitivity. Regulatory documentation does not list specific constraints regarding lactose for this product.

Q: Are there any warnings regarding Benagol Vitamina C and kidney or liver function?

A: The official safety framework outlines specific constraints for certain patient groups. Studies have examined the drug’s effects in individuals with existing kidney issues. Official warnings do not explicitly list liver function impairment as a major contraindication or common risk for the finished product.

Q: Why is it recommended to look for professional advice if symptoms worsen while using Benagol Vitamina C (descriptive)?

A: Official administration guidelines state the requirement to consult a healthcare professional if throat symptoms persist or worsen after a few days of use. This regulatory measure is put in place as a precaution to ensure that any more serious underlying condition is not overlooked.

Q: Can Benagol Vitamina C cause a dry mouth or throat after use?

A: The most frequently observed local effects listed in official safety documents are generally classified as Uncommon. These typically involve localized irritation of the mouth or throat, soreness of the tongue, and oral paraesthesia (a localized tingling or numbness). Dry mouth is not explicitly listed among the uncommon or rare reported adverse reactions.

Q: How does the action of Benagol Vitamina C compare to other types of throat lozenges?

A: Official research evidence states that comparative studies have examined this drug’s effects against older, standard-of-care treatments. The findings showed that the drug’s use was associated with different outcomes in these comparisons. The official documentation defines the product primarily by its own specific antiseptic and pain-modulating action.

Q: Can people with high blood pressure use Benagol Vitamina C?

A: Official regulatory documents do not list high blood pressure, or hypertension, as a specific contraindication for the use of Benagol Vitamina C. There is no official guidance stating that a dosage reduction is required for the elderly, which includes many individuals with this condition.

Q: Does Benagol Vitamina C have any reported effects on dental health or teeth?

A: Official government regulatory documents and safety profiles do not list effects on dental health or teeth as a known adverse reaction associated with the use of this specific lozenge product.

Q: Are there any specific foods or drinks that should be avoided while using Benagol Vitamina C?

A: Official product labeling states there is no documented requirement for users to avoid specific foods or drinks while using Benagol Vitamina C. The only documented constraint relates exclusively to the potential for the Ascorbic Acid (Vitamin C) component to interfere with certain diagnostic laboratory tests, such as those for occult blood.

Q: Has there been research focusing on the Vitamin C content in Benagol Vitamina C?

A: The official product documentation details the Ascorbic Acid (Vitamin C) component’s physiological role in the body. It is defined as an electron-donating antioxidant that works to neutralize free radicals in the local environment. It also acts as an essential cofactor for enzymes involved in the structural integrity of the epithelial barrier.

Q: Can people with a pre-existing throat condition use Benagol Vitamina C?

A: Official regulatory guidance defines contraindications based on known hypersensitivity to the product components and the presence of certain hereditary metabolic disorders. The documentation does not specify contraindications based solely on the presence of general, non-allergic, pre-existing throat conditions.

Q: Is it possible for Benagol Vitamina C to interact with alcohol consumption (informational)?

A: The official product labeling does not document any known clinically significant interaction or restriction regarding the consumption of alcohol while using Benagol Vitamina C. The overall interaction profile is characterized by a general absence of known systemic interaction risks due to the medicine's low systemic exposure.

Q: Is there any research evidence concerning Benagol Vitamina C's impact on virus symptoms?

A: The drug is classified as an oropharyngeal antiseptic which targets microorganisms. The general purpose is to provide symptomatic relief for throat discomfort, often associated with early stages of a cold. Official research evidence specifically focuses on evaluating the drug’s effects on pain and symptom reduction.

Q: Do official documents mention any effects of Benagol Vitamina C on ability to drive?

A: Official regulatory documents and safety profiles do not mention any specific effects of the medicine that would impair a user's ability to drive or operate machinery.

Q: Does Benagol Vitamina C have an expiration date, and how strict is it?

A: All packaged medicines have an expiration date marked on the container to define the period of guaranteed stability and potency. Official documents provide strict instructions for storage, such as not exceeding a maximum temperature of 30 C, and mandate that disposal of unused product must adhere strictly to local regulations.

Q: Is it stated that Benagol Vitamina C is non-drowsy?

A: Official regulatory safety profiles do not list drowsiness among the known or reported adverse reactions for Benagol Vitamina C. The safety framework defines the medicine's risks as predominantly low-frequency, localized effects.

Q: Are there known cross-reactions between Benagol Vitamina C and other medicines containing cetylpyridinium chloride?

A: Official regulatory documentation states that there are no known clinically significant interactions documented for the active antiseptic agents in this product. This general absence of systemic interaction risk is due to the low systemic exposure of the antiseptics.

Q: What is the role of the inactive ingredients in Benagol Vitamina C?

A: Official documents address the role of certain inactive ingredients by noting the constraints they impose on eligibility. For example, the presence of glucose and sucrose must be accounted for in diabetic patients, and the wheat starch excipient leads to a constraint for individuals with a wheat allergy.

Q: Does Benagol Vitamina C help with cough?

A: The general purpose of the lozenge is defined in regulatory documents as symptomatic relief from common soreness and irritation in the throat. The documentation does not state that the product is indicated for the treatment of cough.

Official Storage and Disposal Requirements

This section outlines the storage and disposal constraints for the medicine, as defined in government regulatory documents.

Requirement Type	Official Regulatory Instruction
Maximum Temperature	Do not store above 30 C.
Packaging	Keep in the original PVC-PVDC/Aluminium blisters.
Disposal	Dispose of any unused product and material in accordance with local requirements.

---

Storage Profile

To maintain the quality of Benagol Vitamina C, it is required to store the medicine within a specific temperature range, not exceeding 30 C. The product must remain in its original PVC-PVDC/Aluminium blister packaging to ensure its integrity until use.

Disposal Rules

When discarding unused medicine or waste materials, disposal must adhere strictly to local regulations. This ensures appropriate handling and environmental safety, as mandated by official drug regulatory agencies.